- Home
- GMM vs NXL Comparison
GMM vs NXL Comparison
Compare GMM & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- NXL
- Stock Information
- Founded
- GMM 2017
- NXL 2010
- Country
- GMM China
- NXL United States
- Employees
- GMM N/A
- NXL N/A
- Industry
- GMM
- NXL Medical Specialities
- Sector
- GMM
- NXL Health Care
- Exchange
- GMM Nasdaq
- NXL Nasdaq
- Market Cap
- GMM 9.8M
- NXL 10.0M
- IPO Year
- GMM 2023
- NXL 2022
- Fundamental
- Price
- GMM $3.34
- NXL $2.63
- Analyst Decision
- GMM
- NXL Hold
- Analyst Count
- GMM 0
- NXL 1
- Target Price
- GMM N/A
- NXL N/A
- AVG Volume (30 Days)
- GMM 130.6K
- NXL 542.2K
- Earning Date
- GMM 01-29-2025
- NXL 11-08-2024
- Dividend Yield
- GMM N/A
- NXL N/A
- EPS Growth
- GMM N/A
- NXL N/A
- EPS
- GMM 9.03
- NXL N/A
- Revenue
- GMM $33,985,284.00
- NXL $162,078.00
- Revenue This Year
- GMM N/A
- NXL $56.86
- Revenue Next Year
- GMM N/A
- NXL $167.44
- P/E Ratio
- GMM $0.37
- NXL N/A
- Revenue Growth
- GMM 59.78
- NXL 26.00
- 52 Week Low
- GMM $0.21
- NXL $0.25
- 52 Week High
- GMM $11.50
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- GMM 57.79
- NXL 33.77
- Support Level
- GMM $3.10
- NXL $2.92
- Resistance Level
- GMM $4.15
- NXL $4.49
- Average True Range (ATR)
- GMM 0.53
- NXL 0.40
- MACD
- GMM -0.11
- NXL -0.24
- Stochastic Oscillator
- GMM 19.88
- NXL 4.32
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd, formerly Global Mofy Metaverse Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.